Tamoxifen (Nolvadex) — Clinical FAQs

Question 1

What is Tamoxifen FDA-approved to treat?

Accepted Answer

Tamoxifen is FDA-approved for the following oncology indications: 1. Adjuvant treatment of hormone receptor-positive early breast cancer in pre- and postmenopausal women (5 or 10 years) 2. Treatment of metastatic hormone receptor-positive or hormone receptor-unknown breast cancer in pre- and postmenopausal women and in men 3. Reduction in breast cancer incidence in high-risk women (NSABP P-1 trial; 5-year course) 4. Treatment of ductal carcinoma in situ (DCIS) following breast surgery and radiation to reduce the risk of invasive breast cancer.

Question 2

How does Tamoxifen work (mechanism of action)?

Accepted Answer

Tamoxifen is a selective estrogen receptor modulator (SERM) that competitively binds the estrogen receptor (ER) in a tissue-selective manner. In breast tissue, the tamoxifen–ER complex recruits transcriptional co-repressors rather than co-activators, blocking estrogen-responsive gene transcription and suppressing tumor cell proliferation. Tamoxifen is a prodrug requiring extensive hepatic metabolism — principally via CYP2D6 and secondarily via CYP3A4 — to generate its principal active metabolite endoxifen (4-hydroxy-N-desmethyltamoxifen), which has approximately 30- to 100-fold greater ER binding affinity than the parent compound and accounts for the majority of clinical efficacy. In bone and endometrium, tamoxifen exhibits partial ER agonist activity, conferring bone protection in postmenopausal women while simultaneously increasing the risk of endometrial hyperplasia and carcinoma with long-term use.

Question 3

How is Tamoxifen administered?

Accepted Answer

Tamoxifen is administered Oral (PO). Administer 20 mg orally once daily (or 10 mg twice daily), with or without food.

Question 4

What are the most common side effects of Tamoxifen?

Accepted Answer

The most commonly reported side effects of Tamoxifen (≥10% incidence) include: Hot flashes / vasomotor symptoms (>60%; leading cause of non-adherence), Vaginal discharge, Vaginal dryness or irritation, Menstrual irregularities (oligomenorrhea, amenorrhea) in premenopausal women, Nausea (typically mild) and others (12 total). Consult your oncologist for complete prescribing information.

Question 5

Does Tamoxifen have a black box warning?

Accepted Answer

Yes. Tamoxifen carries FDA black box warning(s) regarding: 1. Uterine malignancies: Tamoxifen is associated with a 2- to 3-fold increased incidence of endometrial adenocarcinoma and an increased risk of uterine sarcoma. Any abnormal vaginal bleeding must be promptly investigated. Annual gynecologic surveillance is required. Benefits must be carefully weighed against uterine cancer risk, particularly when tamoxifen is used for risk-reduction indications in women with an intact uterus. 2. Thromboembolic events: An increased incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) has been observed with tamoxifen, especially when combined with cytotoxic chemotherapy. Risk is highest during the first two years of therapy. Patients with prior thromboembolic events require careful risk–benefit evaluation. 3. Stroke: An increased incidence of stroke was observed in the NSABP P-1 risk-reduction trial. This risk must be weighed against benefits, particularly in women with additional cerebrovascular risk factors.

Question 6

Is Tamoxifen safe during pregnancy?

Accepted Answer

Tamoxifen pregnancy safety: Category D — Tamoxifen causes fetal harm. Animal studies and human case reports demonstrate teratogenicity and embryotoxicity. Females of reproductive potential must use effective non-hormonal contraception during therapy and for at least 9 months after the final dose. Tamoxifen does not reliably suppress ovulation — amenorrhea during therapy does not preclude pregnancy.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Tamoxifen — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms